Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.

Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA 3rd, Shikuma C, Johnson VA, Fiscus SA, D'Aquila RT, Schackman BR, Acosta EP, Gulick RM.

J Infect Dis. 2008 Mar 15;197(6):867-70. doi: 10.1086/528802.

2.

Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.

Bannister WP, Ruiz L, Cozzi-Lepri A, Mocroft A, Kirk O, Staszewski S, Loveday C, Karlsson A, Monforte Ad, Clotet B, Lundgren JD; EuroSIDA study group..

AIDS. 2008 Jan 30;22(3):367-76. doi: 10.1097/QAD.0b013e3282f3cc35.

PMID:
18195563
3.

Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.

Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, Meyer WA 3rd, Johnson VA, Fiscus SA, D'Aquila RT, Gulick RM, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team..

J Infect Dis. 2010 Mar;201(5):662-71. doi: 10.1086/650543.

5.

Safety and efficacy of GSK2248761, a next-generation nonnucleoside reverse transcriptase inhibitor, in treatment-naive HIV-1-infected subjects.

Zala C, St Clair M, Dudas K, Kim J, Lou Y, White S, Piscitelli S, Dumont E, Pietropaolo K, Zhou XJ, Mayers D.

Antimicrob Agents Chemother. 2012 May;56(5):2570-5. doi: 10.1128/AAC.05597-11.

6.

Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.

Shulman N, Zolopa AR, Passaro D, Shafer RW, Huang W, Katzenstein D, Israelski DM, Hellmann N, Petropoulos C, Whitcomb J.

AIDS. 2001 Jun 15;15(9):1125-32.

PMID:
11416714
7.

Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.

Ngo-Giang-Huong N, Jourdain G, Amzal B, Sang-a-gad P, Lertkoonalak R, Eiamsirikit N, Tansuphasawasdikul S, Buranawanitchakorn Y, Yutthakasemsunt N, Mekviwattanawong S, McIntosh K, Lallemant M; Program for HIV Prevention and Treatment (PHPT) study group..

PLoS One. 2011;6(11):e27427. doi: 10.1371/journal.pone.0027427.

8.

Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.

Marcelin AG, Descamps D, Tamalet C, Cottalorda J, Izopet J, Delaugerre C, Morand-Joubert L, Trabaud MA, Bettinger D, Rogez S, Ruffault A, Henquell C, Signori-Schmuck A, Bouvier-Alias M, Vallet S, Masquelier B, Flandre P, Calvez V; ANRS AC11 Resistance Study group..

Antivir Ther. 2012;17(1):119-23. doi: 10.3851/IMP1886.

PMID:
22267476
9.

Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy.

Goodman DD, Zhou Y, Margot NA, McColl DJ, Zhong L, Borroto-Esoda K, Miller MD, Svarovskaia ES.

AIDS. 2011 Jan 28;25(3):325-33. doi: 10.1097/QAD.0b013e3283427dcb.

PMID:
21157296
10.

HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

Puthanakit T, Jourdain G, Hongsiriwon S, Suntarattiwong P, Chokephaibulkit K, Sirisanthana V, Kosalaraksa P, Petdachai W, Hansudewechakul R, Siangphoe U, Suwanlerk T, Ananworanich J; HIV-NAT 086Study Team..

HIV Med. 2010 Oct 1;11(9):565-72. doi: 10.1111/j.1468-1293.2010.00828.x.

11.

The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults.

Mackie NE, Dunn DT, Dolling D, Garvey L, Harrison L, Fearnhill E, Tilston P, Sabin C, Geretti AM; UK HIV Drug Resistance Database.; UK CHIC study..

AIDS. 2013 Sep 10;27(14):2245-53. doi: 10.1097/QAD.0b013e3283636179.

PMID:
24157905
12.

Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.

Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ; Study 934 Team..

J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):209-21. doi: 10.1097/QAI.0b013e3181b05f7c.

PMID:
19644384
13.

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G.

Ann Intern Med. 2007 Apr 17;146(8):564-73.

PMID:
17438315
14.

Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients.

Phillips AN, Pradier C, Lazzarin A, Clotet B, Goebel FD, Hermans P, Antunes F, Ledergerber B, Kirk O, Lundgren JD; EuroSIDA Study Group..

AIDS. 2001 Dec 7;15(18):2385-95.

PMID:
11740189
15.

Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.

Delaugerre C, Rohban R, Simon A, Mouroux M, Tricot C, Agher R, Huraux JM, Katlama C, Calvez V.

J Med Virol. 2001 Nov;65(3):445-8.

PMID:
11596076
16.

Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.

Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, Larouzé B, Verdon R.

Clin Infect Dis. 2004 May 1;38(9):1311-6.

17.

Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure.

Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Kozal MJ, Hullsiek KH, Miller MD, Bangsberg DR, Kuritzkes DR.

AIDS. 2012 Jan 14;26(2):185-92. doi: 10.1097/QAD.0b013e32834e9d7d. Review.

18.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
19.

A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.

Paredes R, Puertas MC, Bannister W, Kisic M, Cozzi-Lepri A, Pou C, Bellido R, Betancor G, Bogner J, Gargalianos P, Bánhegyi D, Clotet B, Lundgren J, Menéndez-Arias L, Martinez-Picado J; EuroSIDA Study Group..

J Infect Dis. 2011 Sep 1;204(5):741-52. doi: 10.1093/infdis/jir385.

20.

Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.

Tozzi V, Zaccarelli M, Narciso P, Trotta MP, Ceccherini-Silberstein F, De Longis P, D'Offizi G, Forbici F, D'Arrigo R, Boumis E, Bellagamba R, Bonfigli S, Carvelli C, Antinori A, Perno CF.

J Infect Dis. 2004 May 1;189(9):1688-95.

Items per page

Supplemental Content

Support Center